Lovastatin, the positive control in this study, was originally isolated from Monascus purpureus and inhibits the activity of HMG-CoA reductase, a rate-limiting enzyme of cholesterol biosynthesis, to lower cholesterol synthesis and thus to treat hypercholesterolemia. This evidence concerns the gene HMGCR and familial hypercholesterolemia.